Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge(University of Colorado Denver), Yung‐Jue Bang(Seoul National University), Eunice L. Kwak(Massachusetts General Hospital), A. John Iafrate(Massachusetts General Hospital), Marileila Varella‐Garcia(University of Colorado Denver), Stephen B. Fox(Peter MacCallum Cancer Centre), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Benjamin Solomon(Peter MacCallum Cancer Centre), Sai‐Hong Ignatius Ou(University of California, Irvine), Dong‐Wan Kim(Seoul National University), Ravi Salgia(University of Chicago), P. Fidias(Massachusetts General Hospital), Jeffrey A. Engelman(Massachusetts General Hospital), Leena Gandhi(Dana-Farber Cancer Institute), Pasi A. Jänne(Dana-Farber Cancer Institute), Daniel B. Costa(Beth Israel Deaconess Medical Center), Geoffrey I. Shapiro(Dana-Farber Cancer Institute), Patricia LoRusso(The Barbara Ann Karmanos Cancer Institute), Katherine Ruffner(Pfizer (United States)), Patricia Stephenson(Rho (United States)), Yiyun Tang(Pfizer (United States)), Keith D. Wilner(Pfizer (United States)), Jeffrey W. Clark(Massachusetts General Hospital), Alice T. Shaw(Massachusetts General Hospital)
Cited by 1,275
Abstract
Related Papers
No related papers found
Powered by citation graph analysis